Purchase this article with an account.
S. K. Seah, A. C. How, R. S. Kumar, Y.-M. Chen, D. Su, F. T. Oen, T. Aung; A Randomized Cross-Over Study Comparing Bimatoprost and Latanoprost in Patients With Primary Angle Closure Glaucoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1217. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effect of latanoprost 0.005% once daily with bimatoprost 0.03% once daily in subjects with primary angle closure glaucoma (PACG).
This was a prospective randomized 3-month open-label observer-masked cross-over study of 60 PACG subjects who had persistently high IOP despite previous laser iridotomy. All subjects were randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The intraocular pressure (IOP)-reducing effect of the medications were assessed by the reduction in IOP after each medication compared to the baseline. The IOP was measured at 9 am and 5 pm on the baseline, Week 6 and Week 12 visits, and at 9 am on Week 2 and Week 8 visits.
Fifty-four patients completed both treatment periods and had IOP data available for evaluation. After 6 weeks of treatment, latanoprost reduced IOP (mean ± SD) by 8.4 ± 3.8 mmHg and bimatoprost by 8.9 ± 3.9 mmHg (p=0.23) from a baseline IOP of 25.2 + 3.6 mmHg and 25.2 + 3.6 mmHg respectively. Adverse ocular symptoms and findings were mild in both treatment groups but occurred at a higher frequency in the bimatoprost treated group (p<0.01). Eye redness and ocular irritation were the most frequently reported events in both treated groups. Bimatoprost had better IOP reduction for patients with higher degree of angle closure and greater extent of peripheral anterior synechiae compared to latanoprost.
In patients with PACG, bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily after 6 weeks of treatment. Both drugs were well tolerated with few ocular adverse events.
Clinical Trial: :
This PDF is available to Subscribers Only